Clinical Trial

A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Study acronym: QLS32015
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of GPRC5D/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with relapsed/refractory multiple myeloma (RRMM).
Trial Details
NCT Number NCT07185477
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Relapsed/Refractory Multiple Myeloma (RRMM)
Enrollment 20 participants
Start Date 2025-09-15
Primary Completion 2027-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-22